<DOC>
	<DOCNO>NCT01582243</DOCNO>
	<brief_summary>This study ass efficacy vildagliptin plus metformin ( SPC ) treatment type 2 diabetes mellitus patient uncontrolled metformin monotherapy 24 week treatment</brief_summary>
	<brief_title>Safety Efficacy Vildagliptin Plus Metformin ( SPC ) Treatment Type 2 Diabetes Mellitus Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion criterion 1 . Outpatients 20 year age old diagnosis T2DM . 2 . Patients treat stable dose metformin ( ≥1000 mg/day ) monotherapy least 4 week prior Visit 1 fail achieve glucose control goal . The glucose control goal define HbA1c ≤ 6.5 % . 3 . Male female childbearing potential agree use effective method contraception approve investigator study . 4 . Understood nature study , sign informed consent form . Exclusion criteria 1 . Patients contraindication mention Summary Product Characteristics vildagliptin metformin . 2 . Patients renal dysfunction define creatinine clearance &lt; 60 ml/min Visit 1 . 3 . Patients history hepatic impairment , include limited pretreatment AST ALT &gt; 3 ULN Visit 1 . 4 . Female patient need lactate study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Diabetes Mellitus , type 2</keyword>
	<keyword>vildagliptin</keyword>
</DOC>